Ganoderic acid BCAS# 81907-61-1 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 81907-61-1 | SDF | Download SDF |
| PubChem ID | 471003 | Appearance | Powder |
| Formula | C30H44O7 | M.Wt | 516.7 |
| Type of Compound | Triterpenoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in acetonitrile and methanol; insoluble in water | ||
| Chemical Name | (2R,6R)-6-[(3S,5R,7S,10S,13R,14R,17R)-3,7-dihydroxy-4,4,10,13,14-pentamethyl-11,15-dioxo-2,3,5,6,7,12,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-methyl-4-oxoheptanoic acid | ||
| SMILES | CC(CC(=O)CC(C)C(=O)O)C1CC(=O)C2(C1(CC(=O)C3=C2C(CC4C3(CCC(C4(C)C)O)C)O)C)C | ||
| Standard InChIKey | LWPLEHFGBRFRKI-NBCWKOIPSA-N | ||
| Standard InChI | InChI=1S/C30H44O7/c1-15(10-17(31)11-16(2)26(36)37)18-12-23(35)30(7)25-19(32)13-21-27(3,4)22(34)8-9-28(21,5)24(25)20(33)14-29(18,30)6/h15-16,18-19,21-22,32,34H,8-14H2,1-7H3,(H,36,37)/t15-,16-,18-,19+,21+,22+,28+,29-,30+/m1/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Ganoderic acid B is a chemical marker in quality control of G. lucidum and related products. Ganoderic acid B-containing herbs has potential influence towards therapeutic window of trifluoperazine.Ganoderic acid B has antinociceptive effect; it is moderately active inhibitors against HIV-1 protease with a 50% inhibitory concentration of 0.17-0.23 mM. |
| Targets | JAK | STAT | IL Receptor | p38MAPK | NF-kB | HIV-1 |
| In vivo | Structural identification of the metabolites of ganoderic acid B from Ganoderma lucidum in rats based on liquid chromatography coupled with electrospray ionization hybrid ion trap and time-of-flight mass spectrometry.[Pubmed: 23723086]Biomed Chromatogr. 2013 Sep;27(9):1177-87.Ganoderic acid B (GAB), a representative triterpenoid in Ganoderma lucidum, possesses various pharmaceutical effects and has been used as a chemical marker in quality control of G. lucidum and related products. |
| Kinase Assay | Ganoderic acid B's influence towards the therapeutic window of trifluoperazine (TFP).[Pubmed: 25834543]Afr Health Sci. 2015 Mar;15(1):146-9.Ganoderic acid B is an important bioactive ingredient isolated from Ganoderma lucidum, and exhibits various pharmacological activities.
To investigate the influence of Ganoderic acid B towards the therapeutic window of trifluoperazine (TFP).
|
Ganoderic acid B Dilution Calculator
Ganoderic acid B Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.9354 mL | 9.6768 mL | 19.3536 mL | 38.7072 mL | 48.384 mL |
| 5 mM | 0.3871 mL | 1.9354 mL | 3.8707 mL | 7.7414 mL | 9.6768 mL |
| 10 mM | 0.1935 mL | 0.9677 mL | 1.9354 mL | 3.8707 mL | 4.8384 mL |
| 50 mM | 0.0387 mL | 0.1935 mL | 0.3871 mL | 0.7741 mL | 0.9677 mL |
| 100 mM | 0.0194 mL | 0.0968 mL | 0.1935 mL | 0.3871 mL | 0.4838 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Forskolin J
Catalog No.:BCN4352
CAS No.:81873-08-7
- Seneciocannabine
Catalog No.:BCN2128
CAS No.:81855-31-4
- Neotriptophenolide
Catalog No.:BCN8059
CAS No.:81827-74-9
- Quinocetone
Catalog No.:BCC9133
CAS No.:81810-66-4
- Methimepip dihydrobromide
Catalog No.:BCC7524
CAS No.:817636-54-7
- Praeruptorin B
Catalog No.:BCN4988
CAS No.:81740-07-0
- Bambuterol
Catalog No.:BCC5431
CAS No.:81732-65-2
- PSI-6130
Catalog No.:BCC1870
CAS No.:817204-33-4
- Rhmannioside D
Catalog No.:BCN2362
CAS No.:81720-08-3
- Rehmannioside C
Catalog No.:BCN8183
CAS No.:81720-07-2
- Rehmannioside B
Catalog No.:BCN8468
CAS No.:81720-06-1
- Rehmannioside A
Catalog No.:BCN2885
CAS No.:81720-05-0
- Ganoderic acid A
Catalog No.:BCN3033
CAS No.:81907-62-2
- 5,19-Epoxy-25-methoxycucurbita-6,23-dien-3-ol
Catalog No.:BCN1341
CAS No.:81910-39-6
- Momordicoside I aglycone
Catalog No.:BCN4353
CAS No.:81910-41-0
- Polyphyllin H
Catalog No.:BCN2834
CAS No.:81917-50-2
- Zofenopril calcium
Catalog No.:BCC5229
CAS No.:81938-43-4
- Z-Ligustilide
Catalog No.:BCC9193
CAS No.:81944-09-4
- 4(15),5,10(14)-Germacratrien-1-ol
Catalog No.:BCN4354
CAS No.:81968-62-9
- Splendoside
Catalog No.:BCN6647
CAS No.:81969-41-7
- Clovin
Catalog No.:BCN7817
CAS No.:81970-00-5
- KW-2478
Catalog No.:BCC2127
CAS No.:819812-04-9
- Hyperxanthone E
Catalog No.:BCN8072
CAS No.:819860-76-9
- Vitedoin A
Catalog No.:BCN6741
CAS No.:819861-40-0
Ganoderic acid B's influence towards the therapeutic window of trifluoperazine (TFP).[Pubmed:25834543]
Afr Health Sci. 2015 Mar;15(1):146-9.
BACKGROUND: Ganoderic acid B is an important bioactive ingredient isolated from Ganoderma lucidum, and exhibits various pharmacological activities. AIMS: To investigate the influence of Ganoderic acid B towards the therapeutic window of trifluoperazine (TFP). METHODS: In vitro human liver microsomes (HLMs) incubation system was used to determine the inhibition of Ganoderic acid B towards the glucuronidation of trifluoperazine (TFP). RESULTS: Ganoderic acid B exerted concentration-dependent inhibition towards the glucuronidation of TFP. Furthermore, Dixon plot was used to determine the inhibition type. The intersection point was located in the second quadrant in Dixon plot, indicating the competitive inhibition of Ganoderic acid B towards TFP glucuronidation. Through fitting the data using competitive nonlinear fitting equation, the inhibition kinetic parameter was calculated to be 56.7 uM. CONCLUSION: All this data indicated the potential influence of Ganoderic acid B-containing herbs towards therapeutic window of TFP. Given that the glucuronidation reaction of TFP is the probe reaction of UGT1A4, the data obtained from the present study also indicated the potential influence of Ganoderic acid-containing herbs towards the therapeutic window of drugs mainly undergoing UGT1A4-mediated metabolism.
Structural identification of the metabolites of ganoderic acid B from Ganoderma lucidum in rats based on liquid chromatography coupled with electrospray ionization hybrid ion trap and time-of-flight mass spectrometry.[Pubmed:23723086]
Biomed Chromatogr. 2013 Sep;27(9):1177-87.
Ganoderic acid B (GAB), a representative triterpenoid in Ganoderma lucidum, possesses various pharmaceutical effects and has been used as a chemical marker in quality control of G. lucidum and related products. The metabolites of GAB in vivo after its oral administration to rats were investigated by liquid chromatography coupled with electrospray ionization hybrid ion trap and time-of-flight mass spectrometry. A total of 14 metabolites of GAB in rat plasma, bile and various organs were detected and identified by direct comparison with the authentic compounds and their characteristic mass fragmentation patterns. The results showed that oxidization and hydroxylation were the common metabolic pathways for GAB in rats. Moreover, some reduction metabolites of GAB were detected in rat kidney and stomach and glucuronidation only appeared in rat bile. This is the first report on the metabolites of GAB in vivo.
